BAJAJ BROKING

Notification
No new Notification messages
Vishal Mega Mart IPO is Open!
Apply for the Vishal Mega Mart IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
glaxosmithkline pharma lt stock

GLAXOSMITHKLINE PHARMA LT Share Price

2304.1 -42.69 (-1.81%)
Dec 12 2024 03:30 PM Pharmaceuticals NSE: GLAXO

GLAXOSMITHKLINE PHARMA LT Share Price Update

As of the latest trading session, GLAXOSMITHKLINE PHARMA LT share price is currently at 2304.1, which is down by -42.69 from its previous closing. Today, the stock has fluctuated between 2297.00 and 2356.30. Over the past year, GLAXOSMITHKLINE PHARMA LT has achieved a return of 39.70 %. In the last month alone, the return has been -7.58 %. Read More...

GLAXOSMITHKLINE PHARMA LT Performance

Day Range

Low2297.00 High2356.30
2304.10

52 Week Range

Low 1661.35 High 3088.00
2304.10

GLAXOSMITHKLINE PHARMA LT Share Price

1153

500660

GLAXO

img img img img
No Data Available

Open Price

2355.00

Prev. Close

2346.80

Volume (Shares)

72480.00

Total traded value

1670.01

Upper Circuit

2816.15

Lower Circuit

1877.45

Note: The current prices & values are delayed, Login to your account for live updates.

GLAXOSMITHKLINE PHARMA LT Fundamentals


(Standalone)

Market Cap (Cr) 39032.84
PE Ratio (TTM) 58.41
Book Value / Share 98.85
Beta 0.54
ROE 36.83%
EPS (TTM) 46.98
Dividend Yield 1.39%
Net Profit Qtr (Cr) 248.69

GLAXOSMITHKLINE PHARMA LT Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 1000.05
Operating Expense 698.23
Net Profit 248.69
Net Profit Margin (%) 24.86
Earnings Per Share (EPS) 14.45
EBITDA 355.83
Effective Tax Rate (%) 26.57
Particulars JUN 2024 (Values in Cr)
Revenue 811.00
Operating Expense 598.36
Net Profit 181.65
Net Profit Margin (%) 22.39
Earnings Per Share (EPS) 10.72
EBITDA 265.27
Effective Tax Rate (%) 26.89
Particulars MAR 2024 (Values in Cr)
Revenue 910.87
Operating Expense 674.43
Net Profit 193.08
Net Profit Margin (%) 21.19
Earnings Per Share (EPS) 11.29
EBITDA 287.58
Effective Tax Rate (%) 28.14
Particulars DEC 2023 (Values in Cr)
Revenue 804.98
Operating Expense 604.90
Net Profit 45.49
Net Profit Margin (%) 5.65
Earnings Per Share (EPS) 2.69
EBITDA 82.53
Effective Tax Rate (%) 30.13
Particulars SEP 2023 (Values in Cr)
Revenue 953.38
Operating Expense 685.33
Net Profit 215.54
Net Profit Margin (%) 22.60
Earnings Per Share (EPS) 12.72
EBITDA 315.05
Effective Tax Rate (%) 27.30
Particulars MAR 2024 (Values in Cr)
Revenue 3407.25
Operating Expense 2578.08
Net Profit 584.69
Net Profit Margin (%) 17.16
Earnings Per Share (EPS) 40.83
EBITDA 880.52
Effective Tax Rate (%) 27.73
Particulars MAR 2023 (Values in Cr)
Revenue 3216.34
Operating Expense 2484.50
Net Profit 607.75
Net Profit Margin (%) 18.89
Earnings Per Share (EPS) 35.88
EBITDA 899.95
Effective Tax Rate (%) 27.35
Particulars MAR 2022 (Values in Cr)
Revenue 3217.51
Operating Expense 2531.85
Net Profit 1690.53
Net Profit Margin (%) 52.54
Earnings Per Share (EPS) 99.79
EBITDA 843.63
Effective Tax Rate (%) 51.31
Particulars MAR 2021 (Values in Cr)
Revenue 2920.47
Operating Expense 2404.83
Net Profit 357.57
Net Profit Margin (%) 12.24
Earnings Per Share (EPS) 21.10
EBITDA 535.36
Effective Tax Rate (%) 36.74
Particulars MAR 2020 (Values in Cr)
Revenue 3224.68
Operating Expense 2655.25
Net Profit 110.05
Net Profit Margin (%) 3.41
Earnings Per Share (EPS) 6.50
EBITDA 411.52
Effective Tax Rate (%) 65.87
Particulars MAR 2024 (Values in Cr)
Book Value / Share 104.93
ROE % 37.32
ROCE % 44.97
Total Debt to Total Equity 0.01
EBITDA Margin 28.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 102.79
ROE % 27.73
ROCE % 33.92
Total Debt to Total Equity 0.01
EBITDA Margin 27.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 157.19
ROE % 81.31
ROCE % 32.55
Total Debt to Total Equity 0.01
EBITDA Margin 25.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 87.26
ROE % 28.86
ROCE % 32.43
Total Debt to Total Equity 0.01
EBITDA Margin 24.23
Particulars MAR 2020 (Values in Cr)
Book Value / Share 107.47
ROE % 9.95
ROCE % 28.51
Total Debt to Total Equity 0.00
EBITDA Margin 22.76
Particulars MAR 2024 (Values in Cr)
Book Value / Share 105.31
ROE % 36.83
ROCE % 44.44
Total Debt to Total Equity 0.01
EBITDA Margin 28.60
Particulars MAR 2023 (Values in Cr)
Book Value / Share 103.48
ROE % 27.43
ROCE % 33.60
Total Debt to Total Equity 0.01
EBITDA Margin 28.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 158.06
ROE % 80.45
ROCE % 32.11
Total Debt to Total Equity 0.01
EBITDA Margin 25.83
Particulars MAR 2021 (Values in Cr)
Book Value / Share 88.37
ROE % 28.49
ROCE % 32.10
Total Debt to Total Equity 0.01
EBITDA Margin 24.24
Particulars MAR 2020 (Values in Cr)
Book Value / Share 108.62
ROE % 9.90
ROCE % 28.38
Total Debt to Total Equity 0.00
EBITDA Margin 22.75
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1063.21
Total Assets 3556.61
Total Liabilities 3556.61
Total Equity 1777.63
Share Outstanding 169406034
Price to Book Ratio 18.45
Return on Assets (%) 16.58
Return on Capital (%) 33.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1155.92
Total Assets 3326.58
Total Liabilities 3326.58
Total Equity 1741.27
Share Outstanding 169406034
Price to Book Ratio 12.80
Return on Assets (%) 18.35
Return on Capital (%) 35.07
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2484.50
Total Assets 4633.27
Total Liabilities 4633.27
Total Equity 2662.95
Share Outstanding 169406034
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.64
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1157.96
Total Assets 3114.64
Total Liabilities 3114.64
Total Equity 1478.25
Share Outstanding 169406034
Price to Book Ratio 16.30
Return on Assets (%) 11.49
Return on Capital (%) 24.23
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1083.20
Total Assets 3135.54
Total Liabilities 3135.54
Total Equity 1820.60
Share Outstanding 169406034
Price to Book Ratio 11.46
Return on Assets (%) 2.97
Return on Capital (%) 5.12
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1061.19
Total Assets 3547.80
Total Liabilities 3547.80
Total Equity 1784.09
Share Outstanding 169406034
Price to Book Ratio 18.45
Return on Assets (%) 16.48
Return on Capital (%) 32.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1150.73
Total Assets 3327.69
Total Liabilities 3327.69
Total Equity 1752.99
Share Outstanding 169406034
Price to Book Ratio 12.80
Return on Assets (%) 18.26
Return on Capital (%) 34.67
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2479.11
Total Assets 4622.59
Total Liabilities 4622.59
Total Equity 2677.61
Share Outstanding 169406034
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.14
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1157.67
Total Assets 3097.07
Total Liabilities 3097.07
Total Equity 1497.11
Share Outstanding 169406034
Price to Book Ratio 16.30
Return on Assets (%) 11.54
Return on Capital (%) 23.88
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1066.40
Total Assets 3131.52
Total Liabilities 3131.52
Total Equity 1840.03
Share Outstanding 169406034
Price to Book Ratio 11.46
Return on Assets (%) 3.51
Return on Capital (%) 5.98
Particulars MAR 2024 (Values in Cr)
Net Income 959.80
Cash from Operations 975.69
Cash from Investing 8.71
Cash from Financing -561.49
Net change in Cash 29.23
Free Cash Flow 1006.91
Particulars MAR 2023 (Values in Cr)
Net Income 841.49
Cash from Operations 755.74
Cash from Investing 807.85
Cash from Financing -1543.32
Net change in Cash -251.24
Free Cash Flow 799.78
Particulars MAR 2022 (Values in Cr)
Net Income 2475.64
Cash from Operations 959.03
Cash from Investing -405.50
Cash from Financing -524.24
Net change in Cash -119.00
Free Cash Flow 993.67
Particulars MAR 2021 (Values in Cr)
Net Income 723.09
Cash from Operations 743.20
Cash from Investing 418.02
Cash from Financing -695.55
Net change in Cash 300.37
Free Cash Flow 787.42
Particulars MAR 2020 (Values in Cr)
Net Income 647.24
Cash from Operations 704.48
Cash from Investing -56.84
Cash from Financing -427.62
Net change in Cash 6.03
Free Cash Flow 860.38
Particulars MAR 2024 (Values in Cr)
Net Income 952.65
Cash from Operations 971.05
Cash from Investing 14.96
Cash from Financing -561.49
Net change in Cash 32.40
Free Cash Flow 1002.27
Particulars MAR 2023 (Values in Cr)
Net Income 837.48
Cash from Operations 757.61
Cash from Investing 805.19
Cash from Financing -1544.17
Net change in Cash -251.04
Free Cash Flow 801.65
Particulars MAR 2022 (Values in Cr)
Net Income 2470.04
Cash from Operations 968.00
Cash from Investing -419.66
Cash from Financing -524.24
Net change in Cash -124.11
Free Cash Flow 1002.64
Particulars MAR 2021 (Values in Cr)
Net Income 722.33
Cash from Operations 760.11
Cash from Investing 407.56
Cash from Financing -695.55
Net change in Cash 306.87
Free Cash Flow 804.33
Particulars MAR 2020 (Values in Cr)
Net Income 646.99
Cash from Operations 704.78
Cash from Investing -63.10
Cash from Financing -427.62
Net change in Cash 0.24
Free Cash Flow 860.68
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.16 37.45 3.55 499.34 37.54 / 77.70
BLISS GVS PHARMA LTD 151.80 19.00 1.58 1598.94 92.25 / 172.40
CIPLA LTD 1454.20 25.44 4.14 117443.01 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 410.00 142.36 4.15 1206.67 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 2349.30
  • 26 Days 2448.90
  • 10 Days 2365.40
  • 50 Days 2515.80
  • 12 Days 2363.30
  • 100 Days 2593.20
  • 20 Days 2403.10
  • 200 Days 2322.50
2350.57
PIVOT
First Resistance 2376.13
Second Resistance 2405.47
Third Resistance 2431.03
First Support 2321.23
Second Support 2295.67
Third Support 2266.33
RSI 37.24
MACD -85.65
Commodity Channel Index (CCI) -101.22
ADX 63.45
Williams % R -77.87

Over 1 Month

down

-7.58

Over 3 Months

down

-17.92

Over 6 Months

down

-11.63

Over 1 Year

down

39.70

Over 3 Years

down

8.02

Over 5 Years

down

7.53

GLAXOSMITHKLINE PHARMA LT Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

GLAXOSMITHKLINE PHARMA LT Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
13.3
Promoter Holdings
75.0
FII
4.36
DII
7.33
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Glaxo Group Limited Shareholding of Promoter and Promoter Group 6.09705E7 35.99
Glaxosmithkline Pte Limited Shareholding of Promoter and Promoter Group 4.7604024E7 28.1
Eskaylab Limited Shareholding of Promoter and Promoter Group 1.176E7 6.94
Burroughs Wellcome International Limited Shareholding of Promoter and Promoter Group 6720000.0 3.97
Life Insurance Corporation Of India - P & Gs Fund Public Shareholding 2244207.0 1.32

GLAXOSMITHKLINE PHARMA LT

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-06-30 32.0 Final 2023-06-30 Equity shares 2022-07-07 30.0 Final 2022-07-08 Equity shares 2022-07-07 60.0 Special 2022-07-08 Equity shares 2021-07-19 30.0 Final 2021-07-20 Equity shares 2020-07-17 20.0 Final 2020-07-20 Equity shares 2020-07-17 20.0 Special 2020-07-20 Equity shares 2019-07-11 20.0 Final 2019-07-15 Equity shares 2018-07-13 35.0 Final 2018-07-17 Equity shares 2017-07-14 30.0 Final 2017-07-18 Equity shares 2016-07-15 50.0 Final 2016-07-19 Equity shares 2015-07-23 62.5 Final 2015-07-25 Equity shares 2014-04-03 50.0 Final 2014-04-07 Equity shares 2013-04-04 50.0 Final 2013-04-08 Equity shares 2012-03-29 45.0 Final 2012-04-02 Equity shares 2011-03-14 40.0 Final 2011-03-16 Equity shares 2010-03-10 30.0 Final 2010-03-12 Equity shares 2009-03-18 22.0 Final 2009-03-20 Equity shares 2009-03-18 18.0 Special 2009-03-20 Equity shares 2008-04-02 18.0 Final 2008-04-04 Equity shares 2008-04-02 18.0 Special 2008-04-04 Equity shares 2007-03-14 17.0 Final 2007-03-16 Equity shares 2007-03-14 14.0 Special 2007-03-16 Equity shares
Ex-Date Ex-Bonus Ratio
2018-09-13 2018-09-11 1:1
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About GLAXOSMITHKLINE PHARMA LT

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GLAXOSMITHKLINE PHARMA LT

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The share price of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 2304.1 and for BSE is ₹ 2306.65.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The market cap of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 3,90,32.84 Cr. and for BSE is ₹ 3,90,76.04 Cr. as of now.

What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 3088.00 and ₹ 1661.35 and for BSE is ₹ 3087.95 and ₹ 1664.75.

How to Buy Glaxosmithkline Pharmaceuticals Ltd share?

Answer Field

You can trade in Glaxosmithkline Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 39.70%.

What is the Current Share Price of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

Glaxosmithkline Pharmaceuticals Ltd share price is for NSE ₹ 2304.1 & for BSE ₹ 2306.65 as on Dec 12 2024 03:30 PM.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glaxosmithkline Pharmaceuticals Ltd for NSE ₹ 3,90,32.84 & for BSE ₹ 3,90,76.04 as on Dec 12 2024 03:30 PM.

What is the P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Dec 12 2024 03:30 PM the price-to-earnings (PE) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 58.41.

What is the PB ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Dec 12 2024 03:30 PM, the price-to-book (PB) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 98.85.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glaxosmithkline Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glaxosmithkline Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glaxosmithkline Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader